jen publically agrees with you and and what I said even before winRT came out, while completely contradicted ibeey - winRT is a dud.
since 2009 i hear this story of the next year!
That means still 1-2 years of pps down!
Terrible strategy , I ask a CEO step down immediately.
Thats the problem with FDA notes.Probuphine worked in the trials but FDA had higher hopes for results.Their unfair expectations is causing this confusion and Titan's presentation tomorrow and along with Advisory committee members hopefully will side with Probuphine and get FDA off their cloud.
FDA wanted to see a grandslam even though Probuphine still hit a homerun out of ballpark.
All the people who have given reply's to this post (excluding me) have written exactly the same reply to 100's of other stocks! Are they just trying to get you to subscribe to another companies take on a particular stock? I guess some will subscribe! There must be an awful lot of real idiots out there!
This is big news - following on from Provenge - this proves beyond doubt that cancer vaccines are the next big thing in cancer! And that the US$1bn acquisition of Biovex has paid off....
Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
THOUSAND OAKS, Calif., March 19, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced top-line results from the Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment with subcutaneous granulocyte-macrophage colony-stimulating factor (GM-CSF).
The study met its primary endpoint of durable response rate (DRR), defined as the rate of complete or partial response lasting continuously for at least six months. A statistically significant difference was observed in DRR: 16 percent in the talimogene laherparepvec arm versus two percent in the GM-CSF arm. The analysis of overall survival (OS), a key secondary endpoint of the study, is event driven. A pre-planned interim analysis conducted with the analysis of DRR has shown an OS trend in favor of talimogene laherparepvec as compared to GM-CSF. The OS data is expected to mature in late 2013 in line with previous guidance.
"These are the first Phase 3 results of this novel approach to cancer therapy," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "A high unmet need exists in melanoma and we believe the innovative mechanism of action of talimogene laherparepvec may offer a promising approach for these patients."
The most frequent adverse events observed in this trial were fatigue, chills and pyrexia. The most common serious adverse events include disease progression, cellulitis and pyrexia.
Among the various types of skin cancer, melanoma is the most aggressive and also the most serious. Although melanoma accounts for less than five percent of skin cancer cases, or 132,000 cases glob
NOW YOU KNOW WHY SHORTS ARE FREAKING.
Sentiment: Strong Buy
Good you have some iq to realize that bbry short days are over
Sentiment: Strong Buy
You've got to realize this is a penny stock. People buy this stock in volume and change handsby minutes for few pennies. Who wants to hold this stock for long periods?
I think its fair to think that today was just the first assault on the $8 level. We'll probably see additional moves in that direction between now and ex-div.
There was bound to be some profit taking once RAS moved over $8 for the first time.
An interesting day mostly because RAS moved so far above $8 early. Not a surprising day.
An heirloom is an object, like your grandmother's tea kettle. I think you mean "heir", or more likely "heiress". More likely a little liar who needs a time-out. "beeb". Seriously, do you have the haircut and everything? Don't call grownups names either kid. That is skill in and of itself that you suck at. Spend some time in front of a mirror working out your material, while you are brushing your hair. Assuming you aren't a 45-year old balding perv with a trucker belly working out your issues with a kid's handle.... I don't know a single person under 30 that knows what malarkey is because that term is virtually extinct from modern English.
Yes, coattails. All the best.
Sentiment: Strong Buy